1. Taiwan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
CARILEX MEDICAL INC.

CARILEX MEDICAL INC.

TTPEX:7726
32.15
TWD
0.00
(0.00%)
655.82MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
25.58
28.41
20.13
26.15
17.32
16.68
- -
Basic EPS, GAAP
3.91
2.37
1.73
2.49
0.66
-1.43
- -
Free Cash Flow per Basic Share
3.26
5.66
0.29
-0.26
1.09
1.78
- -
Dividend per Share
- -
3.55
- -
- -
1.77
0.57
- -
Book Value per Share
10.63
10.03
11.68
17.31
16.26
14.33
14.61
Tangible Book Value per Share
10.6
10
10.78
16.33
15.4
13.6
13.94
Basic Weighted Avg Shares
14
14
17
18
20
20
20
Sales/Revenue/Turnover
347
388
335
466
352
339
- -
Operating Margin (%)
21
13.47
5.24
11.88
0.86
-12.63
- -
Depreciation Expense
17
17
19
21
25
31
- -
Net Income, GAAP
53
32
29
44
13
-29
- -
Effective Tax Rate (%)
20.03
22.63
19.93
21.25
19.38
- -
- -
Profit Margin (%)
15.29
8.34
8.61
9.53
3.83
-8.56
- -
Working Capital
183
177
187
296
277
210
215
LT Debt
28
35
22
7
8
15
4
Total Equity
216
204
237
351
330
291
297
Return on Invested Capital (%)
- -
13.1
7.03
10.7
0.41
- -
- -
Return on Capital (%)
- -
11.24
9.55
12.23
3.56
- -
- -
Return on Common Equity (%)
- -
15.42
13.1
15.1
3.95
-9.33
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
56
157
124
LT Borrowings
- -
- -
- -
LT Finance Leases
5
15
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
843
832
656

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
389
432
436
Cash, Cash Equivalents & STI
160
224
206
Accounts Receivable, Net
60
88
111
Inventories
146
96
95
Total Current Liabilities
132
222
222
Payables & Accruals
- -
- -
- -
ST Debt
56
157
124
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
8.21%
-11.85%
Free Cash Flow
- -
-144.26%
63.49%
Net Income, GAAP
- -
-76.12%
-315.05%
Sales/Revenue/Turnover
- -
1.77%
-3.72%
Total Cash Common Dividend
- -
- -
-67.8%

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
352
2025
- -
- -
339
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.66
2025
- -
- -
-1.43
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.77
2025
- -
- -
0.57
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Chih Wei Wang
Full Time Employees
150
Sector
Distribution services
Industry
Medical distributors
Address
No.77, Keji 1st Road Taoyuan TP Taiwan 33383
IPO Date
Feb 27, 2024
Website
carilexmedical.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Carilex Medical Inc (7726.TWO) manufactures and sells medical devices focused on pressure ulcer prevention and wound care management worldwide. The company offers therapeutic support surfaces including alternating pressure air mattresses such as TheraFlo AP 7&9, DualGT, DualPlus, CozinyPlus, Entrix NX, DualFlex, TheraFlo, AVA LAL, and Envelop; chair cushions like CariChair; and negative pressure wound therapy (NPWT) systems comprising suction pumps such as VT- 100, VT- ONE, and VT- 200, along with NPWT dressing kits and canisters. Founded in 1985 and headquartered in Taoyuan City, Taiwan, Carilex operates globally with subsidiaries and presence in Europe, the United States, Australia, and the Middle East, serving medical wards, acute care units, nursing institutions, and home care settings. In recent developments, the company obtained class IIa CE Mark certification under the EU Medical Device Regulation (MDR) for its alternating pressure air mattresses in 2023; launched innovative NPWT solutions and portable products like VT- ONE for small wound management; expanded market presence through participation in major trade shows including Arab Health 2024, EWMA conferences, Medica 2024, and Taiwan Healthcare Expo; and strengthened its European operations via a UK subsidiary to enhance localized services and NPWT device adoption.